Receive The Newest Study Notifications

Cytel Inc., the leading global provider of analytical solutions to the life sciences industry, today announced that it will launch East On Demand™ at the annual Joint Statistical Meetings (JSM) 2019 (July 27 – August 1, Denver, Colorado). Offered via the cloud and...

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced positive data from its ongoing Phase 1/2 clinical trial evaluating ABO-102, the Company’s investigational one-time, adeno-associated virus 9 (AAV9) gene...

Latest findings show how new drug class could lead to cocktail that breaks the blood-brain barrier The Ivy Brain Tumor Center at the Barrow Neurological Institute, has released the results of its recent Phase 0 clinical trial of the breast cancer drug ribociclib...

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced the progress to date in the Company's special protocol assessment (SPA) phase three clinical trial titled "A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an...

- PathMaker Neurosystems Inc. ("PathMaker"), a clinical-stage bioelectronic medicine company developing breakthrough non-invasive systems for the treatment of patients with spasticity and paralysis announces the first publication of clinical trial results for...

Expect first patient dosing in second half of 2019 DUBLIN, Ireland and CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company,...

Neurocognitive development of youngest patients preserved 12-18 months post treatment; development scores remain within range of unaffected children Robust and sustained biomarker improvement across all dose cohorts with 8 months to 2 years of follow up RMAT meeting...

- Compelling data reported with ADP-A2M4 SPEAR T-cells in synovial sarcoma - - Adaptimmune plans to launch a TCR T-cell therapy in 2022 - Adaptimmune Therapeutics plc (ADAP), a leader in T-cell therapy to treat cancer, has started its SPEARHEAD-1 trial with ADP-A2M4...

A research team led by experts at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center reports favorable five-year survival rates from the first multidose clinical trial of the immunotherapy drug nivolumab (anti-PD-1) as a...

 A Middle East respiratory syndrome coronavirus (MERS CoV) vaccine candidate was shown to be safe, well-tolerated, and induced a robust immune response in a Phase 1 first-in-human clinical trial. Initial findings from the trial were published today in The Lancet...

Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the company has...

- CAPTIVATE clinical trial initiated and enrollment progressing - Evaluating patients with the clinical diagnosis of either constipation or diarrhea predominant irritable bowel syndrome (IBS) - Significant unmet need for pain management in gastrointestinal disorders...

Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced that the first patient has been dosed in the Company's 28-day, Phase...

Alignment reached on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study expected by the end of 2019 Company has implemented measures to ensure the effective...

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announces that the first patient has been treated in the adjuvant (pre-temozolomide maintenance) trial arm...

Study in emergency department shows automated patient screening eases enrollment Clinical trials are a critical tool for getting new treatments to people who need them, but research shows that difficulty finding the right volunteer subjects can undermine the...

- ImaginAb Inc., a clinical-stage immuno-oncology imaging company, announces it has initiated its Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at Dana-Farber Cancer Institute in Boston, MA. Dana-Farber Cancer Institute is a world-renowned...

- Immix receives FDA letter activating the IND for IMX-110 - IND will be expanding ongoing phase 1b/2a clinical trial testing lead candidate Imx-110 from Australia to the United States - Interim readouts from the phase 1b portion of the trial are 100% CBR / DCR (2/2...

Avicanna Inc. ("Avicanna" or the "Company") a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the commencement of phase I clinical trials on three of its...

Noted as the highest scoring vendor in Vision and Capability for Life Sciences Clinical Trials Products REDWOOD SHORES, Calif., July 23, 2019 /PRNewswire/ -- Oracle Health Sciences was positioned as a Leader and the highest scoring vendor in Vision and Capability in...